公司資料
Acumen Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- ABOS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.66 USD (-0.37%)
收盤價
最後更新: 2026年8月17日
171M USD
市值
股價為何變動
As of Aug 17, 2026, ABOS closed down 0.37% at $2.66. No new same-company headline was identified in the current news window.
公司概覽
Alzheimer’s Disease Antibody Company
Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
Sabirnetug
Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers and plaques.
Enhanced Brain Delivery
Acumen is also developing an enhanced brain-delivery platform intended to improve central nervous system exposure of future biologics.
未來催化劑
- Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
- An IND filing for the lead enhanced brain-delivery candidate is targeted for mid-2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。